Company intelligence / Profile preview

Sao Thai Duong Joint Stock Company

Hanoi, Hanoi, Vietnamsaothaiduongglobal.com ↗

Ownership: Private
Employees: ~800
Development stage: Phase 3

Overview

SUNKOVIR, their herbal medicine for COVID-19, was granted marketing authorization by the Ministry of Health of Vietnam in April 2023 after eight clinical trials and preclinical trials. The medicine showed effectiveness in reducing symptoms such as coughs, fever, difficulty in breathing, and other COVID-19 related symptoms[9].

Therapeutic areas: PulmonologyDermatologyInfectious Diseases
Modalities: Herbal medicinesNatural ingredients
Industry: Biotech

Drug pipeline

5 assets

KOVIR

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Sao Thai Duong Joint Stock Company.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sao Thai Duong Joint Stock Company.

Explore the full profile